Cover Image

An interesting case of Sarcoidosis with cutaneous manifestations - A case report

Joel Franklin F, Sujaya Menon, and Mural .

Abstract


Sarcoidosis, a multisystem inflammatory disease of unknown origin characterised by formation of non caseating granulomas known to affect the lungs most commonly. It causes skin manifestations in at least one third of patients. These are usually diagnosed as psoriasis clinically due to similarities. Hence lab investigations such as skin biopsy and correlation with systemic involvement becomes necessary. Here we present a case of Psoriasiform cutaneous sarcoidosis in a 49 year old female patient who presented with features of hypercalcemia and one year history of scaly skin lesions in both lower limbs.Punch biopsy showed presence of multiple non necrotizing granulomas composed of epitheloidhistiocytes, Langhancells suggestive of cutaneous sarcoidosis. She was started on Azathioprine and she improved.

Full Text:

PDF

References


Yanardag H, Pamuk O, Karayel T. Cutaneous involvement in sarcoidosis: analysis of the features in 170 patients. RespirMed. 2003;97:978–982.

Burgoyne J, Wood M.Psoriasiformsarcoidosis. Arch Der matol. 1972;106:896–898.

Reddy RR, Kumar BS, Harish MR. Cutaneous sarcoidosis-a great masquerader: a report of three interesting cases. Indian journal of dermatology. 2011 Sep;56(5):568

Marchell R, Judson M. Chronic cutaneous lesions of sarcoidosis. Clinics in Dermatol. 2007;25:295–302.

Farmer J, Winkelmann K. Psoriasis in association with sarcoidosis. Arch Dermatol. 1960;81:149–152.

Haimovic A, Sanchez M, Judson M, Prystowsky S. Sarcoidosis: a comprehensive review and update for the dermatologist. JAmAcadDermatol. 2012;66 (5):699.e1–719.e10.

Callejas-Rubio J, Ortego-Centeno N, Lopez-Perez L,Benticuaga M. Treatment of therapy-resistant sarcoidosiswithadalimumab. ClinRheumatol. 2006;25:596–597.

Lowes M, Bowcock A, Krueger J. Pathogenesis and therapy of psoriasis. Nature. 2007;445:866–873.

Victor F, Gottlieb A. TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis. J Drugs Dermatol. 2002;1(3):264–275.

Mussi A, Bonifati C, Carducci M, et al. Serum TNF- alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J BiolRegHomeosAg. 1997;11(3):115–118.

Mak RKH, Hundhausen C, Nestle FO. Progress in understanding the immunopathogenesis of psoriasis.ActasDermosifiliogr. 2009;100(Suppl2): 2–13.

Baughman R, Lower E. Evidence-based therapy for cutaneous sarcoidosis. ClinDermatol. 2007;25: 334– 340.

Baughman R, Lower E. Infliximab for refractory sarcoidosis.SarcoidosisVasc Dif. 2001;18:70–74.

Doty J, Mazur J, Judson M. Treatment of sarcoidosis with infliximab. Chest. 2005;127:1064–1071.

Mallbris L, LjungbergA,Hedblad MA, et al. Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy. J Am AcadDermatol. 2003;48:290–293.

Haley H, Cantrell W, Smith K. Infliximab therapy forsarcoidosis (lupus pernio). Br J Dermatol. 2004;150:146–149.

Loza M, Brodmerkel C, Du Bois RM, et al. Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis. Clin Vaccine Immunol. 2011;18(6):931–939.

Aguiar M, Marcal N, Mendes AC, et al. Infliximab for treating sarcoidosis patients, Portuguese experience. Rev Port Pneumol. 2011;17(2):85–93.Keller copy_Layout 1 4/11/16 3:30 PM Page 57


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

An initiative of The Tamil Nadu Dr M.G.R. Medical University